Transforming Lives

Through a new class of safe, durable cancer treatments.

Our Team

Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.
Learn more
Our Science

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.
Learn more
Alliances

Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.
Learn more

Learn More About ONC201 Clinical Trials

In The News

- MAR 29 2018
OncologyTube: Dr. Chi talks about his ONC201 trial in H3 K27M-mutant gliomas
In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of

Read >

- MAR 21 2018
Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects
“Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to

Read >

Press Releases

Jan 14 2019
Oncoceutics Expands Patent Family to Include Use of ONC201 in H3 K27M-Mutant Gliomas

Read >

Events

May 18 2017
ONC201 Abstracts to be Presented at ASCO 2017

Read >
Feb 15 2017
Dr. Josh Allen Presents Webinar on GPCRs With DiscoverX

Read >
Apr 05 2016
Presentations on ONC201 and Analogs at the 2016 AACR Annual Meeting

Read >
Dec 03 2015
Presentations on ONC201 at the 2015 ASH Annual Meeting

Read >